• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[多发性骨髓瘤的生存与治疗。基于56例观察病例]

[Survival and therapy of multiple myeloma. Apropos of 56 observed cases].

作者信息

Locatelli F, Giovanelli E, Neretto G, Furno F, Pellerito R

出版信息

Minerva Med. 1979 Mar 17;70(13):925-33.

PMID:220567
Abstract

56 cases of myeloma observed since 1956 are reviewed and it is noted that course, prognosis and survival have changed in relation to the improvement in diagnostic procedures and therapeutic aids. The recent introduction of polychemotherapeutic approaches based on theoretical considerations has not yet been fully vetted in the clinic although a higher percentage of remissions compared to that obtained by monochemotherapy would seem to be confirmed. Personal experience with a new polychemotherapeutic schema in advanced myeloma resistant to monochemotherapy + prednisone is reported.

摘要

回顾了自1956年以来观察到的56例骨髓瘤病例,注意到随着诊断程序和治疗手段的改进,病程、预后和生存率都发生了变化。基于理论考虑最近引入的多药化疗方法在临床上尚未得到充分验证,尽管与单药化疗相比,似乎有更高比例的缓解得到证实。报告了在对单药化疗+泼尼松耐药的晚期骨髓瘤中使用一种新的多药化疗方案的个人经验。

相似文献

1
[Survival and therapy of multiple myeloma. Apropos of 56 observed cases].[多发性骨髓瘤的生存与治疗。基于56例观察病例]
Minerva Med. 1979 Mar 17;70(13):925-33.
2
[Chemotherapy of multiple myeloma. Review of the recent trials].[多发性骨髓瘤的化疗。近期试验综述]
Recenti Prog Med. 1981 Aug;71(2):141-7.
3
[Recent progress in chemotherapy of multiple myeloma].[多发性骨髓瘤化疗的最新进展]
Recenti Prog Med. 1978 Jul;65(1):44-68.
4
Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.耐药性多发性骨髓瘤。一项使用M2环烷基化剂联合化疗的试验。
Haematologica. 1978 Feb;63(1):45-55.
5
Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Arch Immunol Ther Exp (Warsz). 1981;29(2):145-53.
6
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.AKR淋巴瘤与人类血液肿瘤的化疗比较
Cancer Res. 1974 Jan;34(1):184-93.
7
[Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].[多发性骨髓瘤的治疗。住院患者研究:16年观察中的81例病例]
Minerva Med. 1983 Feb 11;74(5):155-63.
8
[Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)].[多发性骨髓瘤的化疗。历史与现状。(第二部分)(作者译)]
Sem Hop. 1979;55(31-32):1377-82.
9
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.美法仑和泼尼松联合长春新碱、卡莫司汀、美法仑、环磷酰胺及泼尼松治疗多发性骨髓瘤的比较:东部肿瘤协作组E2479研究结果
Cancer. 1997 Apr 15;79(8):1561-7.
10
Polychemotherapy (COMP) treatment in myeloma patients. A preliminary report.骨髓瘤患者的多药化疗(COMP)治疗。初步报告。
Haematologica. 1983 May-Jun;68(3):381-91.

引用本文的文献

1
Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?新的治疗方法(自体移植、沙利度胺、地塞米松)能否提高在风湿科接受治疗的多发性骨髓瘤患者的生存率?
Clin Rheumatol. 2006 Mar;25(2):175-82. doi: 10.1007/s10067-005-1151-4. Epub 2005 Nov 23.